PRME vs. NVAX, HLVX, CABA, KYTX, EXAI, HUMA, VALN, ALLO, PROK, and ALEC
Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Novavax (NVAX), HilleVax (HLVX), Cabaletta Bio (CABA), Kyverna Therapeutics (KYTX), Exscientia (EXAI), Humacyte (HUMA), Valneva (VALN), Allogene Therapeutics (ALLO), ProKidney (PROK), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Prime Medicine (NYSE:PRME) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
Prime Medicine has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Prime Medicine currently has a consensus price target of $16.70, indicating a potential upside of 197.68%. Novavax has a consensus price target of $15.33, indicating a potential upside of 72.67%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Prime Medicine is more favorable than Novavax.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 24.3% of Prime Medicine shares are held by insiders. Comparatively, 0.9% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Novavax had 43 more articles in the media than Prime Medicine. MarketBeat recorded 54 mentions for Novavax and 11 mentions for Prime Medicine. Novavax's average media sentiment score of 0.39 beat Prime Medicine's score of 0.36 indicating that Novavax is being referred to more favorably in the news media.
Prime Medicine has a net margin of 0.00% compared to Novavax's net margin of -55.41%. Novavax's return on equity of 0.00% beat Prime Medicine's return on equity.
Prime Medicine has higher earnings, but lower revenue than Novavax. Prime Medicine is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax received 831 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 74.16% of users gave Novavax an outperform vote while only 71.43% of users gave Prime Medicine an outperform vote.
Summary
Prime Medicine beats Novavax on 9 of the 17 factors compared between the two stocks.
Get Prime Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prime Medicine Competitors List
Related Companies and Tools
